Biolistic Particle Delivery System Market Size & Share, by Type (Electromagnetic, Pneumatic), End User (Research Institutions, Biotechnology, Pharmaceutical Companies) -Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5397
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Biolistic Particle Delivery System Market size is anticipated to reach USD 45 billion by the end of 2036, growing at a CAGR of 12% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of biolistic particle delivery system was over USD 20 billion. The integration of artificial intelligence (AI) is one of the main growth drivers fueling the market. AI integration in Biolistic Particle Delivery Systems can enhance the entire process, from experimental design to execution. AI algorithms can analyze vast datasets, predict optimal parameters for particle delivery, and adapt in real-time to the specific requirements of diverse cell types. This intelligent automation can significantly reduce the time and resources traditionally required for system optimization and experimental setup. A study published demonstrated a 20% improvement in gene delivery efficiency when AI algorithms were employed to optimize particle velocity and penetration depth in a Biolistic system.

Biolistic particle delivery systems, also known as gene guns, are devices used in genetic engineering and biotechnology to introduce foreign genes into target cells. They are commonly used in plant transformation and have applications in genetic research and biopharmaceutical development. Supportive regulatory environments that facilitate the development and commercialization of genetic engineering technologies can positively impact the growth of the market.

Biolistic Particle Delivery System Market
Get more information on this report: Request Free Sample PDF

Biolistic Particle Delivery System Sector: Growth Drivers and Challenges

Growth Drivers

  • Advancements in Genetic Research: Advancements in genetic research stand as a primary driver propelling the growth of the Biolistic Particle Delivery System market. The continuous evolution of genetic science, including breakthroughs in genomics, transcriptomics, and epigenetics, necessitates sophisticated tools for efficient gene delivery. Biolistic particle delivery systems, also known as gene guns, have emerged as indispensable instruments in this landscape. According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has plummeted from millions of dollars to less than a thousand dollars over the past decade.
  • Increased Focus on Genetic Therapies: The increased focus on genetic therapies represents a significant growth driver for the market. As genetic therapies advance, the need for precise and efficient methods of delivering therapeutic genes to target cells becomes paramount, and biolistic particle delivery systems play a crucial role in this domain. Supporting this growth driver is the rise of groundbreaking gene-editing technologies such as CRISPR-Cas9. According to a report, the global CRISPR technology sales are projected to reach USD 10 billion by 2027.
  • Expanding Applications: The expanding applications of genetic engineering and biotechnology across diverse sectors contribute significantly to the growth of the Biolistic Particle Delivery System market. As the understanding of genetics deepens, new avenues for the application of gene delivery systems emerge, creating a demand for versatile and reliable tools like biolistic particle delivery systems. The industrial applications of genetic engineering, including the production of enzymes, biofuels, and other bioproducts, also fuel the demand for gene delivery technologies.


  • Cell Viability and Damage: One significant challenge in the development and application of biolistic particle delivery systems is the potential damage to target cells. The physical force used to propel particles into cells can lead to reduced cell viability and damage to cellular structures. Maintaining cell health and minimizing cellular damage is essential, particularly in applications where high cell viability is critical, such as in therapeutic gene delivery. Despite their versatility, biolistic particle delivery systems may face challenges in achieving high delivery efficiency and precision, especially in complex biological environments.
  • Ethical Concerns Regarding Gene Alteration
  • Scalability for Industrial Applications

Biolistic Particle Delivery System Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 20 Billion

Forecast Year Market Size (2036)

~ USD 45 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Biolistic Particle Delivery System Segmentation

Type (Electromagnetic, Pneumatic)

The pneumatic segment is estimated to account for 61% share of the global biolistic particle delivery system market in the year 2036. Pneumatic biolistic systems exhibit adaptability to various particle types, contributing to their versatility in experimental design. Researchers can utilize different types and sizes of particles depending on the specific requirements of their experiments. This adaptability allows for customization based on the characteristics of the genetic material being delivered and the target cells. Research conducted at the Institute of Plant Sciences, ETH Zurich, utilized pneumatic biolistic systems with a range of particle types, including gold and tungsten, to achieve efficient gene delivery to plant cells. The adaptability to different particles was crucial in optimizing transformation efficiency.

End User (Research Institutions, Biotechnology, Pharmaceutical Companies)

Biolistic particle delivery system market from the pharmaceutical companies segment is expected to garner a significant share in the year 2036. One of the primary growth drivers for pneumatic biolistic systems in pharmaceutical companies is their efficiency in delivering genes for biopharmaceutical production. As the pharmaceutical industry increasingly leans towards biologics, including monoclonal antibodies and recombinant proteins, the precise delivery of therapeutic genes into host cells becomes paramount. Pneumatic systems, with their controlled release of compressed air, enable the efficient transformation of host cells, leading to the expression of the desired biopharmaceuticals. A study published in the "Journal of Biotechnology and Bioengineering" showcased the application of pneumatic biolistic systems for the efficient delivery of genes encoding therapeutic proteins in mammalian cells.

Our in-depth analysis of the global market includes the following segments:


  • Electromagnetic
  • Pneumatic

          End User

  • Research Institutions
  • Biotechnology
  • Pharmaceutical Companies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Biolistic Particle Delivery System Industry – Regional Synopsis

APAC Market Forecast

The biolistic particle delivery system market in the Asia Pacific region is projected to hold the largest market share of 40% by the end of 2036. Collaboration and knowledge exchange initiatives play a crucial role in driving the growth of Biolistic Particle Delivery Systems in the Asia-Pacific region. Academic institutions, research organizations, and biotechnology companies are increasingly engaging in collaborative efforts to share expertise, resources, and best practices in genetic engineering. A study reported a 40% increase in collaborative research projects focusing on gene delivery technologies in the Asia-Pacific region over the past five years. Collaborations foster the exchange of ideas and methodologies, contributing to the refinement and optimization of Biolistic Particle Delivery Systems. Shared knowledge accelerates the adoption of these systems across borders, creating a network of expertise that propels advancements in genetic engineering throughout the Asia-Pacific region.

North American Market Statistics

The biolistic particle delivery system market in the North America region is projected to hold the second largest share during the forecast period. North America is at the forefront of cutting-edge genetic research initiatives, driving the demand for advanced gene delivery systems like Biolistic Particle Delivery Systems. Academic institutions, research centers, and biotechnology companies in the region are actively engaged in unraveling the intricacies of the human genome, studying gene functions, and exploring therapeutic applications of genetic engineering. According to the National Institutes of Health (NIH), North America accounts for approximately 40% of the global research funding dedicated to genetic and genomic studies, indicating a strong commitment to advancing genetic research. The demand for Biolistic Particle Delivery Systems is fueled by the need for precise and efficient methods of introducing foreign genes into cells for functional studies.

Research Nester
Biolistic Particle Delivery System Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Biolistic Particle Delivery System Landscape

    • Bio-Rad Laboratories, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • DuPont de Nemours, Inc.
    • Thermo Fisher Scientific Inc.
    • E. I. du Pont de Nemours and Company
    • Agilent Technologies, Inc.
    • Biorigin
    • BioWorks Inc.
    • Micromeritics Instrument Corporation
    • DuPont Pioneer
    • Particle Sciences Inc.

In the News

  • In 2022, DuPont acquired Microbac Laboratories, Inc., a leading manufacturer of microbial products for industrial, environmental, and food processing applications. The acquisition expanded DuPont's portfolio of microbial solutions and technologies.
  • In 2023, DuPont acquired Spectrum Plastics Group, a recognized leader in specialty medical devices and components markets. The acquisition added Spectrum's best-in-class advanced manufacturing capabilities and decades-long customer relationships to DuPont's existing healthcare portfolio.

Author Credits:  Radhika Pawar

  • Report ID: 5397
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for pharmaceutical sector is the major factor driving the market growth.

The market size of biolistic particle delivery system is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024-2036.

The major players in the market Bio-Rad Laboratories, Inc., DuPont de Nemours, Inc., Thermo Fisher Scientific Inc., E. I. du Pont de Nemours and Company, Agilent Technologies, Inc., Biorigin, and others.

The pharmaceutical companies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Biolistic Particle Delivery System Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying